AstraZeneca Announces an Additional 2300 Layoffs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AstraZeneca Announces an Additional 2300 Layoffs


ePT--the Electronic Newsletter of Pharmaceutical Technology

AstraZeneca announced further downsizing in response to an expected period of declining revenues in the face of patent expirations. The company will eliminate 2300 positions in sales and general administration. When combined with the reduction in R&D headcount of 1600 announced earlier this week, and the elimination of 1150 positions related to restructuring of a Phase III workforce announced in February 2012, the new announcement brings the total headcount reduction to approximately 5050 over the 2013–2016 period.

In a press release, the company outlined five areas of focus intended to return the company to growth.  The company will focus on capturing market share for its platelet aggregation inhibitor, Brilanta (ticagrelor); partner with Bristol Myers-Squibb to achieve a leading position in the noninsulin diabetes market; invest in emerging markets, particularly China; invest in its on-market respiratory portfolio and accelerate its pipeline of respiratory projects; and capture the potential from its established brands and new launches in Japan.

According to the release, the combined program of changes is estimated to incur $2.3 billion in one-time restructuring charges, of which $1.7 billion are expected to be cash costs. Benefits of approximately $800 million per year are expected by 2016.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here